Indication intelligence, analysis and sector perception

Cellectis (CLLS) prices follow-on $175 M ADS offering

April 4, 2018 8:56pm

CLLS closed down -$5.43 or -14.09% - Maintaining SELL

Offering is priced at $31.00 per ADS and the number of ADSs is 5,646,000

The closing of the offering is expected to occur on April 10, 2018, subject to customary closing conditions. The listing of the ordinary shares of Cellectis on Euronext Growth will be suspended on April 5, 2018 until the opening of trading on the NASDAQ market at 3:30 pm (Paris time)

Cellectis S.A. (ALCLS.PA) (CLLS) (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS announced a launch, subject to market conditions, of an underwritten public offering of $175 million of its American Depositary Shares (“ADS”), each representing one ordinary share of CLLS.

Cellectis expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the aggregate offering size.

Goldman Sachs & Co. LLC and Citigroup are acting as book-running managers for the offering. Barclays is also acting as a book-running manager. Nomura is acting as lead

NOTE: In particular, no public offering of the ADSs will be made in Europe.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

8 hours 25 min ago
RegMed Investors’ (RMi) pre-open: It’s “make” a buck day!

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.